STEC, Weronika Maria, KUDAS Zuzanna, GÓRKA Mateusz, WOJTKIEWICZ Anna, PIEKARSKA Magda and SZEREJ Krzysztof. Advancements in Pancreatic Cancer Treatment: A Comprehensive Review of Current Therapies and Future Directions. Quality in Sport. 2024;27:54941. eISSN 2450-3118.
https://dx.doi.org/10.12775/QS.2024.27.54941
https://apcz.umk.pl/QS/article/view/54941

The journal has been 20 points in the Ministry of Higher Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Higher Education and Science of 05.01.2024. No. 32553.
Has a Journal's Unique Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 r. Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398.
Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 05.09.2024. Revised: 18.10.2024. Accepted: 21.10.2024. Published: 22.10.2024.

Review of Advancements in Pancreatic Cancer Treatment: A Comprehensive Review of Current Therapies and Future Directions

1. **Weronika Stec**
https://orcid.org/0009-0009-8495-3573
Independent Public Complex of Health Care Facilities, Marshal Józef Piłsudski in Płońsk, 7 Henryk Sienkiewicz Street , 09-100 Płońsk, Poland
weronikastec1234@gmail.com

2. **Zuzanna Kudas**
https://orcid.org/0009-0009-6750-6886
Independent Public Complex of Health Care Facilities, Marshal Józef Piłsudski in Płońsk, 7 Henryk Sienkiewicz Street, 09-100 Płońsk, Poland
md.zuzannakudas@gmail.com

3. **Mateusz Górka**
https://orcid.org/0009-0009-8495-3573
Voivodeship Integrated Hospital of Stanisław Rybicki in Skierniewice 1 Rybickiego Street 96-100 Skierniewice, Poland https://orcid.org/0009-0004-6201-4691
mateusz.a.gorka@gmail.com

4. **Anna Wojtkiewicz**
https://orcid.org/0009-0002-3451-124X
District Medical Centre in Grójec, 10 Piotra Skargi Street, 05-600 Grójec, Poland
anna.a.wojtkiewicz@gmail.com

5. **Magda Piekarska**
https://orcid.org/0000-0002-3583-8802
Bielanski Hospital, Cegłowska 80, 01-809 Warsaw, Poland madzia12792@gmail.com

6. **Krzysztof Szerej**
https://orcid.org/0009-0003-7581-4965
District Hospital in Sochaczew, Batalionów Chłopskich 3/7, Sochaczew, Poland
krzychszerej@gmail.com

ABSTRACT
Pancreatic cancer still has a 5-year survival rate in the single digits, making it one of the most aggressive and deadly cancers. The therapy of pancreatic cancer presents considerable hurdles because of its late diagnosis, fast development, and resistance to traditional therapies, even with advancements in oncological research. This study offers a thorough summary of the various treatment options available today, including as radiation therapy, chemotherapy, surgery, and the newly recognized roles of immunotherapy and targeted medicines. We examine the most recent advancements in personalized medicine and molecular profiling, which are starting to challenge established therapy paradigms and provide fresh hope for bettering patient outcomes. The study also outlines ongoing clinical trials that attempt to address the shortcomings of current therapy, such as the toxicity and limited efficacy of chemotherapeutic drugs. This study aims to provide a comprehensive overview of the pancreatic cancer therapy landscape by analyzing both conventional and cutting-edge treatments. It also identifies promising directions for future research and clinical practice.

INTRODUCTION
The incidence of pancreatic cancer (PC) has grown in recent years. It is linked to 5% of cancer-related fatalities and around 2% of all cancers. When the disease first begins to grow and progresses to advanced pancreatic metastases, when tumor cells are extremely invasive, the majority of patients do not exhibit any noticeable symptoms.[16] It is becoming one of the most lethal malignant tumors, and early diagnosis is challenging. Even after a potentially drastic treatment, the majority of patients eventually relapse; the patient's 5-year survival rate is only 2%–9%.3. Among PC patients, pancreatic ductal adenocarcinoma (PDAC) is the most prevalent kind.1. Diabetes, pancreatitis, and family history are a few risk factors for PC. Nevertheless, there are currently no global screening programs in place for people who pose a high risk of PC. [1,2]
Pancreatic cancer has historically had few treatment choices, with surgery, chemotherapy, and radiation therapy serving as the mainstays of care. These methods, however, frequently have little to no benefit, particularly for individuals with advanced illness. Due to the intricacies of their biology and inherent resistance to traditional therapies, pancreatic cancers have sparked a vigorous hunt for more potent therapeutic approaches. [3,4]

Recent developments in cancer genetics and molecular biology have opened the door to innovative therapeutic approaches like immunotherapy, targeted treatments, and precision medicine.
These developments, which target the unique molecular features of pancreatic cancers, have the potential to overcome the drawbacks of conventional therapies. Additionally, there appears to be room for improvement in survival results with the combination of multimodal treatment regimens, which combine surgery with adjuvant or neoadjuvant medicines. [5,6]
The goal of this review is to present a thorough summary of the state of pancreatic cancer treatment at the moment. We'll look at the accepted treatments, evaluate new therapy developments, and talk about where this quickly developing field is headed in the future. This review aims to provide a fuller knowledge of the current efforts to enhance pancreatic cancer care and prognosis by highlighting both the achievements and obstacles.

ANATOMY

In humans, the organ known as the pancreas is located in the abdomen, extending from the area below the stomach to the left upper abdomen, close to the spleen. When it is an adult, it measures between 12 to 15 centimeters (4.7 to 5.9 inches) in length, has lobules, and has a salmon color. The pancreas is composed of a head, neck, body, and tail anatomically. The superior mesenteric artery and vein are the two blood arteries that the pancreas surrounds when it extends from the inner curve of the duodenum. The pancreas' body, which is the longest portion, extends below the stomach, while its tail terminates next to the spleen. The pancreas is made up of two ducts: the main pancreatic duct and a smaller auxiliary pancreatic duct. The ampulla of Vater (hepatopancreatic ampulla) is a little ballooning formed by the junction of the common bile duct and the main pancreatic duct. The sphincter of Oddi is a muscle that encircles this ampulla. The duodenum's descending portion is where this ampulla opens.
The sphincter of Boyden regulates the entry of the common bile duct into the main pancreatic duct. Separate apertures above the main pancreatic duct entrance allow the auxiliary pancreatic duct to open into the duodenum. Positioned within the duodenum's curve, the pancreatic head encircles the superior mesenteric artery and vein. [7]
The superior and inferior pancreaticoduodenal arteries pass between the duodenum's descending portion and its right side. The common bile duct and inferior vena cava are located behind. The transverse colon and the peritoneal membrane are positioned in front. Located behind the superior mesenteric vein and occasionally the artery, a tiny uncinate projection protrudes from beneath the head.[12] The pancreatic head, which is situated in the duodenum's curve, is separated from the body by the pancreatic neck. The neck forms in front of the portal vein's formation and is around 2 cm (0.79 in) wide. The neck is covered in peritoneum and is located primarily beneath the stomach's pylorus. The pancreatic neck is traversed by the anterior superior pancreaticoduodenal artery. The pancreas' body, which is its greatest portion, tapering down its length and usually located behind the stomach. The transverse colon is positioned in front of the peritoneum, which is positioned atop the pancreatic body. The aorta, the splenic vein, the left renal vein, and the start of the superior mesenteric artery are among the blood veins located behind the pancreas.
Some of the small intestine lies beneath the pancreatic body; this includes the duodenum's suspensory ligament, which rests between it and the jejunum, and the duodenum's last segment. The transverse colon is situated in front of the pancreas. The tail of the pancreas, which is located next to the spleen, is where it narrows. It lies in the space between the layers of the ligament that connects the left kidney and spleen, usually measuring 1.3 to 3.5 cm (0.51

to 1.38 in) in length. The pancreatic tail is behind the splenic artery and vein, which likewise go behind the organ's body.[7]

RISK FACTORS

Risk factors for PC can be categorized as either modifiable (intestinal microbiota, smoking, alcohol, chronic pancreatitis [CP], obesity, dietary variables, infection) or non-modifiable (age, sex, location, blood group, family history and genetic vulnerability, diabetes). The most important are: age, location, family history, genetic vulnerability, diabetes, smoking, alcohol, diabetes. [8]

AGE

PC primarily affects elderly folks; it is quite uncommon for younger people to get the illness before the age of thirty. Ninety percent of newly diagnosed individuals are older than 55, with the majority being in their seventies or eighties. [9]

LOCATION

Around the world, the prevalence of PCs varies. Asian Americans and Pacific Islanders have the lowest incidence in the United States, while African Americans have a greater incidence than Caucasians.7. The prevalence of cancer is rising in China, and its growth rate in recent years has kept pace with global trends.[5] Urban morbidity and mortality are higher in urban regions than in rural ones, possibly as a result of variations in the socioeconomic environment and lifestyle.8 As of 2018, North America (7.6/10 million) and Europe (7.7/10 million) have the greatest incidence rates of ASR among PC users worldwide (Ocea [6.4/10 million]). Africa has the lowest incidence rate of any continent, with an estimated incidence rate of 2,2/100000 people [9]

FAMILY HISTORY

Recent research indicates that PC clearly has a hereditary foundation, with a family history significantly raising the likelihood of developing the condition. Over 80% of PC cases are caused by sporadic mutations, whereas a tiny percentage are caused by particular genetic changes. PC is mostly caused by genetic and acquired gene mutations. The number of first-degree relatives grows exponentially with the risk of familial PC [5]. Scientists from China and Japan have currently found chromosomal abnormalities at loci 13q22.1, 15q14, 6p25.3, 12p11.21, 7q36.2, 21q21.3, 5p13.1, 21q22.3, 22q13.32, and 10q26.1. New PC susceptibility chromosomal target deletions were found in 7p12, 1p36.33, 8q21.11, 17q12, and 18q21.32, the biggest genome-wide collection in Europe.The most common mutations linked to PC point mutations3,7 in K-RAS, CDKN2A (P16), TP53, SMAD4, BRCA2, BRCA1, STK11, PRSS1, and MMR. [8, 10]

PC stem cells exhibit clear epigenetic modifications, which are mostly attributed to chromatin regulatory protein mutations and the regulation of the epithelial-mesenchymal transition (EMT). Notably, these modifications do not entail alterations in genomic sequence. Since only chemical and DNA chromatin structural alterations are involved, these modifications eventually impact the cell's entire phenotypic state. These concepts have led some researchers to explore the possibility that blocking the process of epigenetic regulation aids in the creation of novel PC treatments. [8, 10]

DIABETES

Those with type 2 diabetes have a roughly two-fold increased risk of pancreatic cancer in comparison to the general population. However, within 1-3 years following the onset of diabetes, particularly in the first 6 months (known as new-onset diabetes [NOD]), there is a marked increase in the risk of pancreatic cancer.

According to a cohort study done through the Mayo Clinic, 85% of patients with PDAC had increased fasting blood sugars and half of them matched clinical criteria for diabetes, which supports the theory that the tumor is the cause of diabetes in this situation. Research conducted on animal models and cell lines indicates that the pancreatic cancer cells themselves generate molecules that hinder glucose metabolism by causing insulin resistance and β-cell malfunction. Depending on the stage at diagnosis, the likelihood of diabetes increases as the cancer spreads and results in gland atrophy in patients with recently discovered pancreatic cancer. Depending on the underlying diabetes prevalence in the control group, risk estimates for PDAC linked to NOD can vary. However, multiple studies have found that 0.5% to 1% of people over 50 with NOD will get a PDAC diagnosis within three years, with the majority of this risk showing symptoms in the first year. Studies are currently concentrated on finding additional clinical and blood-based factors to identify those NOD patients who are most at risk for PDAC involvement, as these reported prevalence rates are probably not high enough to justify an evaluation for undiagnosed pancreatic neoplasia in all diabetic patients. As a result, larger studies are being conducted to determine the value of PDAC screening in the NOD population, while current investigations of the broader NOD population are starting to assess the yield of surveillance among patients with NOD. [11]

Current Therapies for Pancreatic Cancer

Because pancreatic cancer often presents at an advanced stage upon diagnosis and a small number of patients are eligible for surgical resection, the disease has an extremely dismal prognosis, with a median survival of about 10 to 12 months with treatment and 5 to 6 months without treatment. FOLFIRONOX (a combination of 5-fluorouracil [5-FU], leucovorin, irinotecan, and oxaliplatin) or gemcitabine plus albumin-bound (nab) paclitaxel is currently the recommended course of treatment for first-line therapy. [12, 13]Thus far, further combinations have either not demonstrated appreciable survival advantages over these medications or have toxicities that limit the course of treatment. This far, further combinations have either not demonstrated appreciable survival advantages over these medications or have toxicities that limit the course of treatment. But new studies on the genetic and tumor microenvironmental alterations causing pancreatic cancer to originate, spread, and metastasize are identifying unique targets within certain patient subgroups. It could be possible to enhance treatment outcomes for some patients and tailor therapy by identifying these populations early in the diagnosis process. It should be feasible to create novel medications and pharmacological combinations that significantly enhance treatment outcomes for the majority of patients as we gain more understanding of these PDAC driving pathways. [12, 13]

Another therapy for pancreatic cancer are surgical interventions such as pancreaticoduodenectomy. Pancreatoduodenectomy is the usual surgery for resectable cancers. Pancreatoduodenectomy, also known as the Whipple method, involves resectioning the head of the pancreas along with the duodenum, a portion of the stomach, the gallbladder, and the common bile duct. The digestive system is then rebuilt by joining the pancreatic body to the intestine or stomach, as well as the common hepatic duct and stomach to the jejunum. This procedure is dependent on anatomopathological considerations. [14]

Pancreatoduodenectomy with pylorus sparing is the term used to describe a surgery where the entire stomach and the first part of the duodenal pad are preserved (Traverso technique).

Peripancreatic resection, which involves a block progressive resection of the left pancreas along with a resection of the spleen and the retroperitoneal space lymphatic system, is the ideal surgery for malignancies situated in the distal region of the pancreas. [14]
In pancreatic cancer treatment also works great immunotherapy.

Over time, a number of immunotherapy techniques have been developed, including adoptive cell transfer, immunostimulatory cytokines, oncolytic viruses, and tumor-targeting (bi-specific) antibodies. These techniques all function by boosting the immune system's natural ability to fight cancer. Immunocheckpoint inhibitors (ICIs), also known as monoclonal antibodies (mAbs) that block immunosuppressive signals on immune cells or cancer cells, are the most widely used immunotherapies in clinical practice today. They have received many US FDA approvals for use against solid tumors. In certain patient categories, these medicines have shown exciting, long-lasting effects by modifying the immune system's response. [15]

Emerging and Future Therapies

The field of pancreatic cancer treatment is changing quickly as scientists look for new ways to meet the difficult obstacles this aggressive illness presents. Targeting the distinct biology of pancreatic cancer, increasing therapy precision, and fortifying the immune system against tumors are the main goals of emerging medicines. These encouraging advancements give promise for better results in a previously challenging to treat disease. A thorough examination of some of the most intriguing new and developing treatments may be found here.
The first option is synergistic treatment which is such a great option for killing drug-resistant PC cells.[13] For instance, astaxanthin can resensitize human PC cells to gemcitabine by promoting gemcitabine-induced cell death and inhibiting gemcitabine-induced EMT of PC cells through the activation of the hypoxia-inducible factor 1α/STAT3 signaling pathway. DNA methyltransferase 1 is effectively inhibited by guadecitabine, which may resensitize PDAC cells to immune checkpoint blockade therapy (e.g., anti-PD-L1). [16]
To address the shortcomings of current treatments, namely in terms of overcoming drug resistance and enhancing efficacy, new pharmacological therapies are being developed.
Novel Chemotherapeutic drugs: A number of new chemotherapeutic drugs, such as gemcitabine and FOLFIRINOX, are being tested in clinical settings with the goal of either replacing or improving current regimens. These medications are intended to target cancer cells more precisely and have fewer side effects. They are also intended to be less toxic and more potent.
Drug Delivery with Nanotechnology: Drug delivery for pancreatic cancer is being improved with nanotechnology. Chemotherapeutic drugs can be delivered to the tumor site directly by use of tailored nanoparticles, which enhances drug accumulation within the tumor and lowers systemic toxicity. [16]

In the treatment of pancreatic cancer, immunotherapy - which uses the body's immune system to combat cancer - is gaining popularity.
Checkpoint Inhibitors: Because of the immunosuppressive nature of the tumor microenvironment, immune checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors, have revolutionized the treatment of some cancers but have not been as successful in pancreatic cancer patients. [17, 18] The goal of ongoing research is to maximize the efficacy of checkpoint inhibitors by combining them with other treatments like radiation, chemotherapy, or targeted pharmaceuticals. [17, 18]
Neoantigen-Based Vaccines: An intriguing area of immunotherapy is the development of personalized cancer vaccines that specifically target neoantigens, or tumor-specific mutations.

[18] The goal of these vaccinations is to boost the immune system's capacity to identify and combat cancer cells more successfully. Clinical trials in the early stages are being conducted to assess their potential in pancreatic cancer. [18]
Adoptive Cell Therapy: CAR-T cell therapy, which entails training a patient's T cells to identify and eliminate cancer cells, is being modified for solid tumors like pancreatic cancer after demonstrating efficacy in treating blood malignancies. [18]
Targeting particular tumor antigens, TCR-T treatments are also being developed. Although these methods have obstacles to overcome, such as the immunosuppressive environment and thick stroma of pancreatic tumors, advances in cell engineering could result in breakthroughs. [18]

Tumor Microenvironment Modulation
Immunosuppressive cells that shield the tumor from therapy and a thick stroma are features of the tumor microenvironment in pancreatic cancer. Changing this setting is an important field of study.[19]
Therapies that target the extracellular matrix and stromal cells around the tumor are known as "stromal targeting" therapies, and their goal is to increase the tumor's accessibility to medication and immune cells. For instance, the capacity of pegvorhyaluronidase alfa (PEGPH20) to break down hyaluronan, a stroma component that obstructs medication delivery, has been studied. [19]
Desmoplastic Reaction Reduction: Treatment efficacy is restricted by the desmoplastic reaction, a fibrotic response in the tumor microenvironment. To improve drug penetration and lower tumor resistance, methods to lessen this reaction - such as inhibitors of the Hedgehog signaling pathway - are being investigated. [19]

Artificial Intelligence and Machine Learning
Research on pancreatic cancer is changing as a result of machine learning and artificial intelligence (AI), which make it possible to develop more individualized and precise treatment plans. [20]
Precision medicine: large-scale genomic, clinical, and imaging data can be analyzed by AI-driven algorithms to find trends and forecast treatment outcomes.This makes it possible to create more individualized treatment regimens that are specific to the tumor features of each patient, increasing results and minimizing needless side effects.[20]
Predictive Modeling: Using their distinct clinical and molecular profiles, machine learning models are being created to forecast which treatments will be most effective for patients with pancreatic cancer. These models can be used to identify patients who are most likely to benefit from new medicines and to assist guide treatment decisions.[20]

Clinical Trials and Ongoing Research
A strong pipeline of clinical trials powers the quick speed of innovation in pancreatic cancer treatment. In order to advance the standard of care and validate the safety and efficacy of novel medicines, these trials are essential.[21]
Combination Therapies: A primary emphasis of clinical trials is the combination of various modalities, such as immunotherapy and chemotherapy or targeted therapy. Through several targeted attacks on the tumor, these combinations seek to overcome the limits of single-agent therapy.
Biomarkers and Personalized Approaches: Biomarker-driven studies are becoming more and more significant since they make it possible to identify patients who will respond most likely to particular treatments. Studies on biomarkers such tumor-infiltrating lymphocytes (TILs)

and circulating tumor DNA (ctDNA) are opening the door to more individualized and efficient therapies. [21]

CONCLUSION

Given its high death rate and dearth of efficient treatment options, pancreatic cancer continues to rank among the most difficult cancers to cure. Notwithstanding these obstacles, substantial advancements have been made recently, giving patients new hope. Though they remain essential components of care, conventional therapies like radiation, chemotherapy, and surgery are being supplemented by more cutting-edge techniques that are revolutionizing the field of medicine.

Thanks to developments in molecular and genetic understanding, patients now have more accurate and efficient alternatives for treatment based on their individual tumor profiles thanks to personalized medicine and targeted medicines. Although it is still in its infancy, immunotherapy shows promise in the treatment of pancreatic cancer, particularly when paired with other interventions. Furthermore, cutting-edge methods like gene editing, nanotechnology, and AI-powered precision medicine are expanding the realm of what is feasible in the treatment of cancer.

Significant obstacles still need to be overcome in spite of these developments, most notably the disease's resistance to treatment, delayed detection, and the intricate tumor microenvironment. To overcome these challenges and turn scientific discoveries into real-world advantages for patients, further research and clinical trials are required.In the future, it will be critical to integrate multimodal therapy, make progress in early detection, and work internationally to guarantee fair access to novel treatments. Even if the future is uncertain, there is cause for optimism due to the speed at which innovation is occurring. There is hope that pancreatic cancer treatment will continue to advance with continued attention to research and clinical advancement, ultimately leading to improved results and a brighter future for patients.

Authors' contribution

Conceptualization: Weronika Stec and Zuzanna Kudas

Methodology: Mateusz Górka and Magda Piekarska

Software: Mateusz Górka, Krzysztof Szerek

Check: Anna Wojtkiewicz, Magda Piekarska

Formal Analysis: Magda Piekarska

Investigation: Weronika Stec

Data Curation: Krzysztof Szerej Writing-Rough Preparation: Zuzanna Kudas

Writing-Review and Editing: Magda Piekarska

Visualization: Weronika Stec

Supervision: Weronika Stec

Project Administration: Krzysztof Szerej

All authors have read and agreed with the published version of the manuscript.

Funding statement:
The study did not receive special funding

Institutional review board statement:
Not applicable.

Informed consent statement:
Not applicable
Data availability statement:
Not applicable

Conflict of interest:
The authors declare no conflict of interest

REFERENCES

1. Mazer BL, Lee JW, Roberts NJ, Chu LC, Lennon AM, Klein AP, Eshleman JR, Fishman EK, Canto MI, Goggins MG, Hruban RH. Screening for pancreatic cancer has the potential to save lives, but is it practical? Expert Rev Gastroenterol Hepatol. 2023 Jan-Jun;17(6):555 574. doi: 10.1080/17474124.2023.2217354. Epub 2023 Jul 3. PMID: 37212770; PMCID: PMC10424088.
2. Stoffel EM, Brand RE, Goggins M. Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. Gastroenterology. 2023 Apr;164(5):752-765. doi: 10.1053/j.gastro.2023.02.012. Epub 2023 Feb 18. PMID: 36804602; PMCID: PMC10243302
3. Atkinson MA, Campbell-Thompson M, Kusmartseva I, Kaestner KH. Organisation of the human pancreas in health and in diabetes. Diabetologia. 2020 Oct;63(10):1966-1973. doi: 10.1007/s00125-020-05203-7. Epub 2020 Sep 7. PMID: 32894306; PMCID: PMC7565096.
4. Kolbeinsson, H. M., Chandana, S., Wright, G. P., & Chung, M. (2022). Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. *Journal of Investigative Surgery*, *36*(1). https://doi.org/10.1080/08941939.2022.2129884
5. Bärthel S, Falcomatà C, Rad R, Theis FJ, Saur D. Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. Nat Cancer. 2023 Apr;4(4):454-467. doi: 10.1038/s43018-023-00526-x. Epub 2023 Mar 23. PMID: 36959420; PMCID: PMC7615362.
6. Ngo P, Shanshal M, Rojan A. Immunotherapy in pancreatic cancer and the importance of tumour testing. BMJ Case Rep. 2020 Jul 16;13(7):e235774. doi: 10.1136/bcr-2020-235774. PMID: 32675128; PMCID: PMC7368477.
7. Mastracci TL, Apte M, Amundadottir LT, Alvarsson A, Artandi S, Bellin MD, Bernal-Mizrachi E, Caicedo A, Campbell-Thompson M, Cruz-Monserrate Z, El Ouaamari A, Gaulton KJ, Geisz A, Goodarzi MO, Hara M, Hull-Meichle RL, Kleger A, Klein AP, Kopp JL, Kulkarni RN, Muzumdar MD, Naren AP, Oakes SA, Olesen SS, Phelps EA, Powers AC, Stabler CL, Tirkes T, Whitcomb DC, Yadav D, Yong J, Zaghloul NA, Pandol SJ, Sander M. Integrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases:

Workshop Proceedings. Diabetes. 2023 Apr 1;72(4):433-448. doi: 10.2337/db22-0942. Erratum in: Diabetes. 2023 Aug 1;72(8):1173. doi: 10.2337/db23-er08. PMID: 36940317; PMCID: PMC10033248.
8. Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY, Gao F. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021 Jul 21;27(27):4298-4321. doi: 10.3748/wjg.v27.i27.4298. PMID: 34366606; PMCID: PMC8316912.

9. Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M; International Cancer of the Pancreas Screening (CAPS) consortium. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020 Jan;69(1):7-17. doi: 10.1136/gutjnl-2019-319352. Epub 2019 Oct 31. Erratum in: Gut. 2020 Jun;69(6):e3. doi: 10.1136/gutjnl-2019-319352corr1. PMID: 31672839; PMCID: PMC7295005.
10. Pereira SP, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, Li D, Greenhalf W, Jeon CY, Koay EJ, Almario CV, Halloran C, Lennon AM, Costello E. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020 Jul;5(7):698-710. doi: 10.1016/S2468-1253(19)30416-9. Epub 2020 Mar 2. PMID: 32135127; PMCID: PMC7380506.
11. Zhao Z, Liu W. Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820962117. doi: 10.1177/1533033820962117. PMID: 33357065; PMCID: PMC7768873.
12. Park W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021 Sep 7;326(9):851-862. doi: 10.1001/jama.2021.13027. Erratum in: JAMA. 2021 Nov 23;326(20):2081. doi: 10.1001/jama.2021.19984. PMID: 34547082; PMCID: PMC9363152.
13. Garajová I, Peroni M, Gelsomino F, Leonardi F. A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists. Curr Oncol. 2023 Oct 31;30(11):9587-9601. doi: 10.3390/curroncol30110694. PMID: 37999114; PMCID: PMC10669959.
14. Di Martino M, El Boghdady M. Pancreatic cancer surgery. BMC Surg. 2023 Jul 7;23(1):196. doi: 10.1186/s12893-023-02091-7. PMID: 37420195; PMCID: PMC10329289.
15. Mukherji R, Debnath D, Hartley ML, Noel MS. The Role of Immunotherapy in Pancreatic Cancer. Curr Oncol. 2022 Sep 23;29(10):6864-6892. doi: 10.3390/curroncol29100541. PMID: 36290818; PMCID: PMC9600738.
16. Zhou Z, Edil BH, Li M. Combination therapies for cancer: challenges and opportunities. BMC Med. 2023 May 4;21(1):171. doi: 10.1186/s12916-023-02852-4. PMID: 37143031; PMCID: PMC10161484.
17. Jiang QY, Chen ZX, Zhang S, Xue RY. Future therapies for pancreatic carcinoma: Insights into cancer precision medicine. World J Gastroenterol. 2022 Jun 14;28(22):2523-2526. doi: 10.3748/wjg.v28.i22.2523. PMID: 35979258; PMCID: PMC9258281.

18. Liu L, Huang X, Shi F, Song J, Guo C, Yang J, Liang T, Bai X. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. J Exp Clin Cancer Res. 2022 Feb 9;41(1):56. doi: 10.1186/s13046-022-02273-w. PMID: 35139879; PMCID: PMC8827285.
19. Wei D, Wang L, Zuo X, Maitra A, Bresalier RS. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Clin Cancer Res. 2024 Feb 16;30(4):655-662. doi: 10.1158/1078-0432.CCR-23-2098. PMID: 37831007; PMCID: PMC10922474.
20. Huang B, Huang H, Zhang S, Zhang D, Shi Q, Liu J, Guo J. Artificial intelligence in pancreatic cancer. Theranostics. 2022 Oct 3;12(16):6931-6954. doi: 10.7150/thno.77949. PMID: 36276650; PMCID: PMC9576619.
21.Schalck A, Sakellariou-Thompson D, Forget MA, Sei E, Hughes TG, Reuben A, Bai S, Hu M, Kumar T, Hurd MW, Katz MHG, Tzeng CD, Pant S, Javle M, Fogelman DR, Maitra A, Haymaker CL, Kim MP, Navin NE, Bernatchez C. Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discov. 2022 Oct 5;12(10):2330-2349. doi: 10.1158/2159-8290.CD-21-1248. PMID: 35849783; PMCID: PMC9547957.